Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myositis | 17 | 2024 | 41 | 10.440 |
Why?
|
| Dermatomyositis | 3 | 2024 | 16 | 2.030 |
Why?
|
| Sarcoidosis | 2 | 2020 | 14 | 1.330 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2024 | 434 | 1.160 |
Why?
|
| Rheumatology | 5 | 2024 | 90 | 0.980 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2024 | 11 | 0.920 |
Why?
|
| Polymyositis | 1 | 2023 | 10 | 0.900 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 63 | 0.860 |
Why?
|
| Vasculitis, Central Nervous System | 2 | 2020 | 8 | 0.850 |
Why?
|
| Fitness Trackers | 1 | 2022 | 15 | 0.830 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 330 | 0.820 |
Why?
|
| Humans | 29 | 2024 | 30959 | 0.820 |
Why?
|
| Myasthenia Gravis | 1 | 2022 | 13 | 0.820 |
Why?
|
| Myocarditis | 1 | 2022 | 11 | 0.810 |
Why?
|
| Muscle Strength | 2 | 2023 | 136 | 0.760 |
Why?
|
| Muscle Weakness | 1 | 2021 | 34 | 0.750 |
Why?
|
| Activities of Daily Living | 2 | 2022 | 551 | 0.740 |
Why?
|
| Adult | 12 | 2024 | 8924 | 0.740 |
Why?
|
| Osteoporosis | 1 | 2022 | 85 | 0.730 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2020 | 9 | 0.730 |
Why?
|
| Central Nervous System Diseases | 1 | 2020 | 23 | 0.680 |
Why?
|
| Tattooing | 1 | 2019 | 3 | 0.670 |
Why?
|
| Microscopic Angioscopy | 1 | 2019 | 1 | 0.660 |
Why?
|
| Capillaries | 1 | 2019 | 13 | 0.660 |
Why?
|
| Microcirculation | 1 | 2019 | 42 | 0.660 |
Why?
|
| Neoplasms | 1 | 2022 | 261 | 0.650 |
Why?
|
| Scleroderma, Systemic | 1 | 2019 | 18 | 0.650 |
Why?
|
| Skin Diseases | 1 | 2019 | 29 | 0.640 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2018 | 11 | 0.610 |
Why?
|
| Leukocytes | 1 | 2018 | 46 | 0.610 |
Why?
|
| Flow Cytometry | 1 | 2018 | 204 | 0.590 |
Why?
|
| Prospective Studies | 5 | 2023 | 1897 | 0.580 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2019 | 221 | 0.520 |
Why?
|
| Exercise | 3 | 2022 | 507 | 0.430 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 817 | 0.410 |
Why?
|
| Female | 10 | 2023 | 16965 | 0.360 |
Why?
|
| Consensus | 3 | 2024 | 112 | 0.320 |
Why?
|
| Male | 9 | 2023 | 16425 | 0.310 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 1922 | 0.310 |
Why?
|
| Fatigue | 2 | 2023 | 66 | 0.270 |
Why?
|
| Pain | 3 | 2023 | 426 | 0.260 |
Why?
|
| Quality of Life | 4 | 2023 | 697 | 0.240 |
Why?
|
| Lymphotoxin-alpha | 1 | 2024 | 7 | 0.230 |
Why?
|
| Chemokines | 1 | 2024 | 29 | 0.230 |
Why?
|
| Global Health | 1 | 2024 | 58 | 0.230 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 1009 | 0.220 |
Why?
|
| Research Design | 1 | 2024 | 219 | 0.210 |
Why?
|
| Middle Aged | 6 | 2023 | 10192 | 0.210 |
Why?
|
| Monitoring, Ambulatory | 1 | 2022 | 20 | 0.210 |
Why?
|
| Muscles | 1 | 2022 | 72 | 0.200 |
Why?
|
| Physicians | 1 | 2023 | 119 | 0.200 |
Why?
|
| Cytokines | 1 | 2024 | 351 | 0.200 |
Why?
|
| Glucocorticoids | 1 | 2022 | 71 | 0.190 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2021 | 18 | 0.190 |
Why?
|
| Information Systems | 1 | 2021 | 23 | 0.190 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 93 | 0.190 |
Why?
|
| Attitude to Health | 1 | 2021 | 100 | 0.190 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 1 | 0.180 |
Why?
|
| Gels | 1 | 2020 | 12 | 0.180 |
Why?
|
| Long Term Adverse Effects | 1 | 2020 | 1 | 0.180 |
Why?
|
| Behcet Syndrome | 1 | 2020 | 5 | 0.180 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 58 | 0.180 |
Why?
|
| Prednisone | 1 | 2020 | 69 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 31 | 0.180 |
Why?
|
| Biomarkers | 1 | 2024 | 733 | 0.180 |
Why?
|
| Demography | 1 | 2020 | 81 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 103 | 0.170 |
Why?
|
| Internship and Residency | 1 | 2023 | 227 | 0.170 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 138 | 0.170 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 407 | 0.160 |
Why?
|
| Tissue Fixation | 1 | 2018 | 11 | 0.150 |
Why?
|
| Depressive Disorder | 1 | 2019 | 191 | 0.150 |
Why?
|
| Aftercare | 1 | 2017 | 23 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 1311 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2023 | 3806 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2017 | 136 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1505 | 0.140 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 53 | 0.140 |
Why?
|
| Disease Management | 1 | 2017 | 126 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2017 | 132 | 0.130 |
Why?
|
| Education, Medical, Graduate | 2 | 2023 | 88 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2019 | 1055 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 1210 | 0.070 |
Why?
|
| Rare Diseases | 1 | 2024 | 14 | 0.060 |
Why?
|
| Research Personnel | 1 | 2024 | 21 | 0.060 |
Why?
|
| Rituximab | 1 | 2023 | 55 | 0.060 |
Why?
|
| Mentors | 1 | 2024 | 49 | 0.060 |
Why?
|
| Faculty | 1 | 2023 | 17 | 0.050 |
Why?
|
| Emigrants and Immigrants | 1 | 2022 | 20 | 0.050 |
Why?
|
| Career Choice | 1 | 2022 | 31 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 45 | 0.050 |
Why?
|
| Self Report | 1 | 2023 | 231 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2023 | 429 | 0.050 |
Why?
|
| Equipment Design | 1 | 2021 | 181 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2023 | 241 | 0.050 |
Why?
|
| Exercise Test | 1 | 2021 | 128 | 0.050 |
Why?
|
| Infertility | 1 | 2020 | 8 | 0.050 |
Why?
|
| Pandemics | 1 | 2022 | 274 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2020 | 3658 | 0.040 |
Why?
|
| Child | 1 | 2024 | 1428 | 0.040 |
Why?
|
| Cerebral Angiography | 1 | 2019 | 33 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2019 | 138 | 0.040 |
Why?
|
| Aged | 2 | 2023 | 10047 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2017 | 164 | 0.030 |
Why?
|
| United States | 1 | 2022 | 2373 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 830 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 1672 | 0.030 |
Why?
|
| Risk Factors | 1 | 2017 | 2586 | 0.020 |
Why?
|